Virax Biolabs Group Ltd (VRAX) Retained Earnings (2021 - 2025)

Virax Biolabs (VRAX) has 5 years of Retained Earnings data on file, last reported at -$24.6 million in Q1 2025.

• In Q1 2025, Retained Earnings fell 32.71% year-over-year to -$24.6 million; the TTM figure through Mar 2025 stood at -$24.6 million (down 32.71% YoY), while the FY2025 annual figure was -$24.6 million, down 32.71% from the prior year.
• Retained Earnings declined to -$24.6 million in Q1 2025, from -$18.5 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$1688.0 in Q1 2023 and bottomed at -$24.6 million in Q1 2025.
• A 5-year average of -$8.6 million and a median of -$2764.0 in 2021 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings jumped 34.91% — and 2024, when it tumbled 1097530.15%.
• Year by year, Retained Earnings stood at -$2764.0 in 2021, then soared by 34.91% to -$1799.0 in 2022, then advanced by 6.17% to -$1688.0 in 2023, then tumbled by 1097530.15% to -$18.5 million in 2024, then slumped by 32.71% to -$24.6 million in 2025.
• The last three Retained Earnings figures came in at -$24.6 million (Q1 2025), -$18.5 million (Q1 2024), and -$1688.0 (Q1 2023), per Business Quant data.

Peer Comparison